#Japan #Osaka #Glico #Lactobacillus #GCL1815

Glico's Lactobacillus GCL1815: A Breakthrough in Immune Cell Activation

In a groundbreaking study, Ezaki Glico Co., Ltd. has revealed the potential of its proprietary lactobacillus strain, Lactobacillus helveticus GCL1815 (referred to as GCL1815), in boosting immune responses. Researchers have confirmed that GCL1815 activates dendritic cells, which are crucial for initiating immune reactions, leading to improved T-cell responses. Published in the esteemed journal, Biochemistry and Biophysics Reports, this research sheds light on the mechanisms behind Glico's previously reported benefits, such as alterations in immune indicators and alleviation of cold-like symptoms.

Key Findings of the Research

1. Activation of Dendritic Cells: The study demonstrated that GCL1815 enhances the expression of critical factors necessary for T-cell responses, including the activation of dendritic cells. This process is vital for the immune system's ability to fight infections and respond effectively to pathogens.

2. Stimulation of T-cell Function: Investigations revealed that GCL1815-activated dendritic cells significantly boosted the proliferation of both CD4+ and CD8+ T cells. Notably, the production of interferon-gamma (IFN-γ), essential for viral infection defense, increased substantially in CD8+ T cells.

3. Mechanism of Action: Further analysis involved inhibiting receptors responsible for recognizing bacterial components. Experiments indicated that blocking TLR2 (Toll-like receptor 2) suppressed IL-12 production, whereas TLR4 inhibition had no effect. This suggests that certain components of the GCL1815 cell wall may play a role in modulating immune responses.

Implications of the Study

The findings from this research indicate that GCL1815 not only enhances the initial immune response (natural immunity) but also has a positive influence on subsequent defense mechanisms (acquired immunity). This could lead to greater understanding and utilization of GCL1815’s immunomodulatory effects in health supplements and functional foods.

By demonstrating that GCL1815 activates dendritic cells and facilitates T-cell responses on a cellular level, Glico highlights the probiotic strain's potential in enhancing overall immune health. These advancements complement previous human trials confirming reductions in cold symptoms and improvements in health indicators among subjects ingesting GCL1815.

Future Directions

Glico aims to continue its exploration of GCL1815, with a focus on illuminating its mechanisms of action and validating its benefits in health perspectives. The company's commitment aligns with its mission of promoting a